Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Flaherty

Showing results (321-330 of 580) with videos related to

Pageof 58
Sort By:
Frontiers in Oncology|August 17, 2019
Novel Diphenylamine Analogs Induce Mesenchymal to Epithelial Transition in Triple Negative Breast CancerAkshita B Bhatt, Mohit Gupta, Van T Hoang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2016
Myc-Driven Glycolysis Is a Therapeutic Target in GlioblastomaKensuke Tateishi, A John Iafrate, Quan Ho, et al.
Clinical Pharmacology and Therapeutics|September 20, 2016
PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial PlatformsM R Trusheim, A A Shrier, Z Antonijevic, et al.
Plos One|March 26, 2013
The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signalingBrijal M Desai, Jessie Villanueva, Thierry-Thien K Nguyen, et al.
Cancer Chemotherapy and Pharmacology|April 14, 2010
Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumorsAnne M Traynor, Maureen Hewitt, Glenn Liu, et al.
Cancer|June 8, 2012
Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapyDaniel C Cho, Thomas E Hutson, Wolfram Samlowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2019
Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway ActivationVictoria E Wang, Jenny Y Xue, Dennie T Frederick, et al.
Cancer Research|January 11, 2007
An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cellsKeiran S M Smalley, Rooha Contractor, Nikolas K Haass, et al.
Journal of Virology|August 1, 1997
Pathogenesis of simian immunodeficiency virus encephalitis: viral determinants of neurovirulenceJ L Mankowski, M T Flaherty, J P Spelman, et al.
Cancer Discovery|September 27, 2014
The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFαMichael P Smith, Berta Sanchez-Laorden, Kate O'Brien, et al.
Pageof 58

Showing results (321-330 of 580) with videos related to

Sort By:
Pageof 58
Frontiers in Oncology|August 17, 2019
Novel Diphenylamine Analogs Induce Mesenchymal to Epithelial Transition in Triple Negative Breast CancerAkshita B Bhatt, Mohit Gupta, Van T Hoang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2016
Myc-Driven Glycolysis Is a Therapeutic Target in GlioblastomaKensuke Tateishi, A John Iafrate, Quan Ho, et al.
Clinical Pharmacology and Therapeutics|September 20, 2016
PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial PlatformsM R Trusheim, A A Shrier, Z Antonijevic, et al.
Plos One|March 26, 2013
The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signalingBrijal M Desai, Jessie Villanueva, Thierry-Thien K Nguyen, et al.
Cancer Chemotherapy and Pharmacology|April 14, 2010
Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumorsAnne M Traynor, Maureen Hewitt, Glenn Liu, et al.
Cancer|June 8, 2012
Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapyDaniel C Cho, Thomas E Hutson, Wolfram Samlowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2019
Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway ActivationVictoria E Wang, Jenny Y Xue, Dennie T Frederick, et al.
Cancer Research|January 11, 2007
An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cellsKeiran S M Smalley, Rooha Contractor, Nikolas K Haass, et al.
Journal of Virology|August 1, 1997
Pathogenesis of simian immunodeficiency virus encephalitis: viral determinants of neurovirulenceJ L Mankowski, M T Flaherty, J P Spelman, et al.
Cancer Discovery|September 27, 2014
The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFαMichael P Smith, Berta Sanchez-Laorden, Kate O'Brien, et al.
Pageof 58